New combo aims to shrink bile duct tumors before surgery
NCT ID NCT07599995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether giving a combination of chemotherapy (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) before surgery can reduce tumor cells in patients with bile duct cancer at high risk of recurrence. About 34 adults aged 18-80 with resectable biliary tract cancer will receive the drugs for several cycles, then undergo surgery. The main goal is to see how many patients have a major pathologic response, meaning few or no cancer cells remain in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gemcitabine, Cisplatin, and Envafolimab
What this could lead to
If successful, this approach could shrink tumors before surgery, potentially lowering the chance of cancer coming back in high-risk patients.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply broadly. Chemotherapy and immunotherapy can cause serious side effects like low blood counts or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••